PepGen Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; balance-sheet comparisons are to December 31, 2023. PepGen is a clinical-stage biotechnology company developing peptide-conjugated oligonucleotide therapeutics using its Enhanced Delivery Oligonucleotide (EDO) platform. It has no approved products and has generated no revenue.
Key financial metrics
| Metric | Q1 2024 / March 31, 2024 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $14.7 million | $14.4 million in Q1 2023 |
| General and administrative expense | $5.1 million | $3.7 million in Q1 2023 |
| Total operating expenses / operating loss | $19.8 million | $18.0 million in Q1 2023 |
| Interest and other income, net | $1.8 million | $1.7 million in Q1 2023 |
| Net loss | $18.0 million; $0.63 per share | $16.3 million; $0.69 per share in Q1 2023 |
| Operating cash used | $22.5 million | $15.4 million in Q1 2023 |
| Cash and cash equivalents | $133.9 million | $80.8 million at December 31, 2023 |
| Marketable securities | $41.4 million | $29.6 million at December 31, 2023 |
| Total liabilities | $28.0 million, including $19.8 million of operating lease liabilities | $34.6 million at December 31, 2023 |
Combined cash, cash equivalents and marketable securities were $175.2 million at quarter-end. The company reported no product revenue, so profit margins are not meaningful. No borrowings or other financial debt are identified in the supplied filing text; lease liabilities are reported. The company reported an accumulated deficit of $199.5 million.
Changes versus prior comparable period
- Net loss increased by $1.7 million year over year as operating expenses rose by $1.8 million; higher other income partly offset the increase.
- R&D expense increased $0.4 million. Management cited higher clinical-trial and personnel costs, partly offset by lower preclinical and manufacturing costs.
- G&A expense increased $1.4 million, primarily from personnel-related costs and facility expenses.
- Operating cash use increased $7.1 million year over year. The company attributed much of Q1 2024’s working-capital outflow to a $6.8 million decrease in accrued expenses, including lower R&D accruals and payment of annual employee bonuses.
- Q1 financing provided $87.0 million, principally from the February follow-on offering and at-the-market (ATM) sales. The offerings increased shares outstanding and diluted existing holders.
Outlook, programs and risks
- Management estimates existing cash, cash equivalents and marketable securities will fund operations into 2026, based on current plans. The notes also state resources are expected to cover at least the next 12 months. Both estimates are forward-looking and depend on assumptions; management expects to seek additional capital over time.
- Management expects R&D expense to increase for the remainder of 2024 as clinical programs advance; it expects G&A expense to remain generally consistent with 2023.
- PGN-EDO51 (Duchenne muscular dystrophy): CONNECT1, an open-label Phase 2 study in Canada, began dosing in January 2024; its first 5 mg/kg cohort was fully enrolled. Preliminary safety, exon-skipping and dystrophin data were expected in mid-2024. The UK regulator cleared the multinational, placebo-controlled CONNECT2 Phase 2 study in February 2024; the filing describes planned dosing every four weeks for six months. The FDA granted orphan-drug and rare-pediatric-disease designations in March 2024.
- PGN-EDODM1 (myotonic dystrophy type 1): The FREEDOM Phase 1 study was dosing participants, with preliminary data expected in the second half of 2024. The FDA lifted a prior clinical hold in October 2023 and granted Fast Track designation in February 2024. A Phase 2 FREEDOM2 study was planned for the second half of 2024.
- Other programs: PGN-EDO53 remained in preclinical and IND/CTA-enabling work; the company also cited exon 45 and 44 programs.
- Development remains early-stage and carries substantial clinical, regulatory, manufacturing and financing uncertainty. The filing highlights dependence on third-party manufacturers and CROs, limited oligonucleotide/peptide manufacturing capacity, competition, enrollment challenges, and patent and funding risks.
- In the completed PGN-EDO51 Phase 1 study, the company reported generally good tolerability at clinically active doses, but also described transient kidney-biomarker changes, mild-to-moderate hypomagnesemia, and one non-life-threatening serious adverse event at 15 mg/kg that was treated with brief hospitalization and intravenous hydration.
- The company reported no material legal proceedings, no litigation reserves, effective disclosure controls as of March 31, 2024, and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether CONNECT1 and FREEDOM preliminary data were subsequently reported, and how the complete safety, exon-skipping, dystrophin, splicing-correction and functional results compare with company expectations.
- Whether CONNECT2 and FREEDOM2 commenced on schedule, their enrollment and dose plans, and any updated regulatory feedback on a potential accelerated-approval path for PGN-EDO51.
- Whether the stated runway into 2026 remains achievable as trial activity and cash use increase; monitor quarterly operating cash burn and any further financing.
- The terms and share-count impact of the Q1 equity issuances: 7.53 million follow-on shares and 1.0 million ATM shares, with $86.3 million combined net proceeds.
- Potential dilution and ownership concentration: RA Capital-affiliated entities held 33.0% and OSE held 14.7% of common stock at March 31, 2024; the filing also reports approximately 47.7% ownership by executive officers, directors, greater-than-5% holders and affiliates collectively.
- Manufacturing capacity and continuity, clinical-trial execution and enrollment, and the strength and scope of the company’s early-stage patent portfolio.